Memphis, TN – A pivotal new study from scientists at St. Jude Children’s Research Hospital has fundamentally reshaped our understanding of secondary cancer risk in survivors of childhood cancer. The research, published today in The Lancet Oncology, is the first to precisely quantify the contributions of both a survivor’s genetic makeup and their life-saving pediatric cancer treatments to the development of subsequent malignancies. This landmark finding is set to revolutionize long-term survivorship care, emphasizing that a holistic view encompassing genetic predisposition alongside treatment history is crucial for effective risk assessment and prevention.
Secondary cancers represent the leading cause of mortality for long-term childhood cancer survivors, a stark reality that underscores the urgency of this research. By meticulously analyzing data from two of the world’s most extensive childhood cancer survivor studies – the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS) – researchers have provided an unprecedented, population-level attribution of risk factors. This revelation is poised to guide physicians toward more personalized and proactive screening strategies, ultimately extending and improving the lives of a growing population of survivors.
“We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition,” stated corresponding author Yadav Sapkota, PhD, from the St. Jude Department of Epidemiology and Cancer Control. “We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level.”
Unraveling the Complex Tapestry of Risk: Main Facts
The core finding of the St. Jude study is a definitive quantification of how various factors contribute to the risk of secondary cancers in childhood cancer survivors. For years, clinicians and researchers have acknowledged that both the intensive, often toxic, treatments for pediatric cancers and a patient’s inherent genetic vulnerabilities play a role. However, the precise relative contribution of these factors at a population scale remained largely unexplored until now.
This new research unequivocally demonstrates that a survivor’s genetic predisposition can be as, or even more, significant than certain chemotherapy exposures in determining their risk for a secondary cancer. While radiation exposure remains the single largest contributor, accounting for 40% or more of the risk, the study highlights the often underappreciated role of genetics, which can contribute between 5% and 37% of risk depending on the cancer type. This challenges conventional wisdom and calls for a significant recalibration of current clinical practices in survivorship care.
The comprehensive analysis drew upon an unparalleled dataset of over 10,000 survivors, allowing for a robust examination of treatment exposures, genetic information (including both common polygenic risk scores and rare variants), lifestyle factors, and the ultimate development of secondary cancers. The meticulous dissection of these factors provides a clearer roadmap for future interventions, focusing efforts where they can yield the greatest impact on prevention, early detection, and treatment of subsequent diseases.
A Historical Perspective: The Chronology of Survivorship Challenges
The journey of childhood cancer survivorship has been one of remarkable progress, yet persistent challenges. Decades ago, a diagnosis of childhood cancer often carried a grim prognosis. Advances in chemotherapy, radiation therapy, and surgical techniques have dramatically improved survival rates, transforming what was once a near-certain death sentence into a treatable condition for many. Today, more than 80% of children diagnosed with cancer survive five years or more. However, this triumph has brought with it a new frontier of medical challenge: the long-term health consequences faced by these survivors.
The Emergence of Late Effects: As survival rates climbed, it became increasingly apparent that the very treatments saving these young lives were also exacting a toll on their long-term health. These "late effects" can manifest in various forms, including cardiovascular problems, endocrine disorders, cognitive impairments, and crucially, secondary cancers. By the 1970s and 80s, large-scale studies like the CCSS began to track these survivors, revealing the extent and severity of these late effects. It became clear that managing these long-term health issues was as vital as the initial cancer treatment itself.
Early Focus on Treatment Toxicity: Initial research into secondary cancers naturally focused on the known toxicities of cancer treatments. Radiation therapy, in particular, was quickly identified as a potent carcinogen, capable of inducing new cancers in irradiated fields years or decades after treatment. Chemotherapy agents were also implicated, though their mechanisms and variable risks were more complex. Clinical guidelines for survivorship care largely revolved around monitoring for treatment-related late effects, including screening for secondary cancers based on the types and doses of therapies received.
The Growing Awareness of Genetic Predisposition: While the role of treatment was paramount, the medical community also acknowledged that some individuals seemed inherently more susceptible to both primary and secondary cancers. This led to a gradual recognition of genetic predisposition, with rare inherited cancer syndromes being identified. However, for the vast majority of survivors, the interplay between common genetic variations, treatment exposures, and secondary cancer risk remained largely unquantified at a population level. The challenge was to move beyond anecdotal observations and rare syndromes to understand how genetics influenced risk for the broader survivor population.
Addressing the Knowledge Gap: This St. Jude study marks a crucial chronological step in this evolution. Previous research had examined specific treatment exposures, genetic factors, or lifestyle choices in isolation. What was missing was a comprehensive, integrated analysis that could assign proportional contributions to each factor across a large and diverse cohort of survivors. This is precisely the knowledge gap that Dr. Sapkota and his team set out to fill, utilizing the unique power of the St. Jude LIFE and CCSS cohorts. Their work represents a maturation of survivorship research, moving from identifying risk factors to quantifying their relative impact, thereby paving the way for truly personalized risk stratification.
The Power of Data: Supporting Data and Key Findings
To bridge the critical knowledge gap, St. Jude scientists embarked on an ambitious comparative analysis, leveraging the unparalleled resources of the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS). These two cohorts collectively represent the largest survivor population in North America, providing an invaluable treasure trove of longitudinal data essential for understanding long-term health outcomes.
“This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing,” highlighted co-author Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control. This extensive dataset included detailed records of original cancer diagnoses and treatments, comprehensive genetic information obtained through advanced sequencing, self-reported lifestyle factors, and meticulously documented occurrences of secondary cancers. This holistic data allowed the researchers to build sophisticated models to evaluate the independent and combined contributions of these diverse factors.
Radiation: The Dominant Player, Yet Undergoing Change
The study confirmed radiation exposure as the most significant contributor to secondary cancer risk, accounting for approximately 40% or more of the total risk. This finding aligns with decades of prior research demonstrating the DNA-damaging effects of radiation, which can lead to malignant transformations in irradiated tissues. Radiation therapy, while highly effective in treating many childhood cancers, involves exposing healthy tissues to ionizing radiation, increasing the risk of subsequent solid tumors like breast cancer, thyroid cancer, and sarcomas.
However, the researchers also noted the positive implications of this finding: modern pediatric oncology has already made significant strides in reducing radiation doses or eliminating radiation altogether in favor of more targeted and less toxic therapies. This study further validates those efforts, suggesting that continued de-escalation of radiation will have a profound impact on reducing future secondary cancer burdens.
Genetics: A Hidden, Yet Potent, Force
Perhaps the most striking and counter-intuitive finding concerned the role of genetic predisposition. While the late effects of chemotherapy have been extensively described, the proportional contribution of genetics to secondary cancer risk in survivors was less recognized and certainly not quantified at a population level.
To better understand this predisposition, the researchers employed a sophisticated approach. They examined hundreds of common genetic variants previously associated with cancer development in the general population, aggregating their effects into what is known as a polygenic risk score (PRS). They also analyzed the impact of certain rare genetic variants. This polygenic risk score approach revealed that, depending on the specific type of secondary cancer, genetics contributed a substantial 5% to 37% of the overall risk.
“Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field,” Dr. Sapkota emphasized. This paradigm-shifting insight suggests that a survivor’s inherent genetic blueprint plays a far more critical role than previously assumed, sometimes overshadowing the impact of chemotherapy in predisposing them to subsequent malignancies.
Chemotherapy: Variable Contributions Across Cancer Types
Chemotherapy’s contribution to subsequent cancer risk was found to be highly variable, ranging from 8% to 35%, depending on the specific type of secondary cancer being considered. This variability is not surprising, given the vast array of chemotherapy agents, their differing mechanisms of action, and their distinct profiles of acute and late toxicities. Alkylating agents, topoisomerase inhibitors, and antimetabolites are known to be associated with an increased risk of certain secondary leukemias and solid tumors, but their impact can differ significantly based on dose, duration, and individual patient factors. This nuanced understanding underscores the complexity of chemotherapy-related risks and highlights the need for continued research into individual drug effects.
Lifestyle Factors: An Evolving Picture
In contrast to radiation, genetics, and chemotherapy, lifestyle factors such as diet, physical activity, and smoking appeared to contribute much less to second cancer risk in this study, accounting for only 1% to 6%. However, the researchers cautioned against underestimating their long-term importance. The survivor cohort primarily consisted of individuals in their 20s and 30s, an age range where the cumulative effects of lifestyle choices on cancer risk may not yet be fully apparent.
“We know healthy lifestyle choices are important for survivors,” Dr. Sapkota clarified. “In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle.” This nuanced perspective acknowledges that while lifestyle’s direct impact on secondary cancer risk might be less pronounced in younger cohorts, its overall importance for general health and other late effects remains undeniable.
Official Responses and Expert Commentary
The publication of this study in The Lancet Oncology is being met with significant interest and endorsement from the oncology and survivorship communities. The clear, quantified data provides concrete evidence that supports a shift in clinical practice and research priorities.
Dr. Yutaka Yasui, co-author and a distinguished figure in the St. Jude Department of Epidemiology and Cancer Control, provided crucial context on the utility of polygenic risk scores: “Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures.” This expert assessment suggests that while PRSs may have limitations in the general population, their predictive power is amplified and becomes clinically meaningful within the unique context of childhood cancer survivors, where treatment exposures already create a heightened baseline risk.
The St. Jude Leadership Perspective: The institutional commitment of St. Jude Children’s Research Hospital to long-term survivorship care is underscored by this research. St. Jude has pioneered the field of survivorship medicine, establishing dedicated clinics and research programs focused on the health of childhood cancer survivors. This study is a direct outcome of that sustained investment and vision. The emphasis on the St. Jude LIFE and CCSS cohorts, both housed at St. Jude, highlights the institution’s role as a global leader in gathering and analyzing longitudinal data critical for understanding the lifelong impact of childhood cancer and its treatments. The findings reinforce St. Jude’s mission to not only save lives but to ensure those lives are lived as fully and healthily as possible.
Implications for the Clinical Community: For pediatric oncologists, survivorship specialists, and primary care physicians caring for these patients, the message is clear: genetic predisposition must now be integrated more formally into risk assessment. This will likely necessitate broader adoption of genetic testing and counseling for survivors, moving beyond screening for rare inherited syndromes to incorporating polygenic risk information. Genetic counselors will play an increasingly vital role in interpreting these complex risk profiles for both clinicians and patients.
Empowering Survivors and Advocacy Groups: This research also empowers childhood cancer survivors and their families. Armed with knowledge about their unique combination of treatment-related, genetic, and lifestyle risk factors, survivors can become more active participants in their own healthcare. They can better advocate for tailored screening protocols and discuss personalized prevention strategies with their healthcare providers. Patient advocacy groups will likely champion the integration of these findings into standard care, ensuring that all survivors have access to comprehensive risk assessments.
Charting the Future: Implications for Survivorship Care
The implications of this groundbreaking St. Jude study are profound and far-reaching, promising to transform the landscape of childhood cancer survivorship care.
1. Revolutionizing Risk Stratification and Personalized Screening:
The most immediate and impactful implication is the shift towards truly personalized risk stratification. “Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk,” Dr. Sapkota noted. “Our study suggests that we need to better account for genetic predisposition in this population.” This means moving beyond a ‘one-size-fits-all’ approach to survivorship care. Survivors with a high genetic predisposition, in combination with specific treatment exposures, could receive more intensive and frequent screenings tailored to their unique risk profile. For example, a survivor with a high polygenic risk score for breast cancer, coupled with chest radiation exposure, might warrant earlier and more frequent mammograms or MRIs compared to a survivor with lower genetic risk and similar treatment. This precision medicine approach aims to catch secondary cancers earlier, when they are most treatable, dramatically improving prognosis.
2. Integrating Genetic Testing and Counseling:
The study strongly advocates for a more widespread integration of genetic testing and counseling into routine survivorship care. Currently, genetic testing for cancer risk is often reserved for individuals with strong family histories or features suggestive of inherited cancer syndromes. This research suggests that a broader assessment, including polygenic risk scores, could be beneficial for all childhood cancer survivors. Genetic counselors will become indispensable in helping both survivors and their physicians understand and navigate these complex genetic insights, explaining what a polygenic risk score means for an individual and how it should inform their health management.
3. Informing Future Treatment Decisions:
While the study primarily focuses on survivorship care, its findings also have potential implications for initial cancer treatment planning. As our understanding of genetic predisposition grows, future pediatric oncology protocols might incorporate genetic profiling to guide treatment choices. For instance, if a child has a high genetic predisposition to a certain secondary cancer, clinicians might favor alternative treatments that carry a lower risk of inducing that specific secondary malignancy, if equally effective. This would represent a truly proactive approach to preventing late effects.
4. Guiding Prevention Strategies and Lifestyle Advice:
While lifestyle factors contributed a smaller proportion of risk in this young cohort, the study underscores that this does not diminish their overall importance for health. Future research, particularly on older survivor cohorts, will be crucial to fully elucidate the long-term impact of lifestyle on secondary cancer risk. In the meantime, clinicians must continue to encourage healthy lifestyle choices for overall well-being, including cardiovascular health, metabolic health, and prevention of other late effects. Empowering survivors with their complete risk profile – genetic, treatment, and lifestyle – allows for more informed decision-making and adherence to preventive measures.
5. Fueling Future Research and Policy:
This study opens numerous avenues for future research. Scientists will delve deeper into specific genetic variants and their interactions with different treatment exposures. Further studies are needed to refine polygenic risk scores and explore their clinical utility in diverse survivor populations. From a policy perspective, there will be a need to develop guidelines and ensure equitable access to advanced genetic testing and personalized survivorship care across healthcare systems. Continued funding for large-scale, longitudinal studies like St. Jude LIFE and CCSS is paramount to building upon these foundational discoveries.
In conclusion, Dr. Sapkota succinctly summarized the overarching goal: “Second cancers remain the leading cause of mortality for childhood cancer survivors. Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives.” This landmark research from St. Jude Children’s Research Hospital not only quantifies risk but illuminates a clearer path toward a future where childhood cancer survivors can live longer, healthier lives, free from the shadow of secondary disease.
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors are Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui; St. Jude; Qi Liu; University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia; University of Minnesota; Monica Gramatges, Baylor College of Medicine; Rebecca Howell, University of Texas MD Anderson Cancer Center and Smita Bhatia; University of Alabama at Birmingham.
The study was supported by grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude.
About the Author
